Potent activity against a broad range of gram-positive and gram-negative pathogens, including clinically significant anaerobes14,15
Increased utilization of INVANZ® was associated with an increase as shown in the percentage of gram-negative bacteria susceptible to imipenem and other antibiotics tested22-24
Efficacy comparable to piperacillin/tazobactam in complicated intra-abdominal infections33 and diabetic foot infections28 with the potential to spare Pseudomonas selection in clinical trials11,24,25
Once-daily empiric monotherapy
INVANZ® is indicated for complicated intra-abdominal infections, community-acquired pneumonia, complicated urinary tract infections, acute pelvic infections and complicated skin/skin structure infections including diabetic foot infections, without osteomyelitis.
Methicillin-resistant staphylococci are resistant to INVANZ®. Many strains of Enterococcus faecalis and most strains of Enterococcus faecium are resistant. Clostridium difficile is also resistant.
Excluding Enterococcus spp, Clostridium difficile, and methicillin-resistant Staphylococcus spp.
d
In patients with advanced renal insufficiency (creatinine clearance ≤30 mL/min/1.73 m2) including those on hemodialysis, the dose of INVANZ is 500 mg daily.
